Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.
대표청구항▼
1. A formulation for the controlled release of octreotide after implantation into a subject comprising a preparation substantially encased in a polyurethane based hydrophilic polymer, wherein the preparation comprises octreotide, wherein the formulation is effective to permit release of octreotide a
1. A formulation for the controlled release of octreotide after implantation into a subject comprising a preparation substantially encased in a polyurethane based hydrophilic polymer, wherein the preparation comprises octreotide, wherein the formulation is effective to permit release of octreotide at a rate of about 30 μg to about 800 μg per day over about six months in vivo, and wherein the polyurethane based hydrophilic polymer but not the preparation further comprises a release agent with a molecular weight of at least about 1000 Daltons. 2. The formulation of claim 1, wherein the release agent is a non-ionic surfactant. 3. The formulation of claim 2, wherein the non-ionic surfactant comprises a polyethylene glycol hydrophilic tail and a lipophilic head. 4. The formulation of claim 1, wherein the release agent is selected from the group consisting of: Brij 35, polyoxyethylene(20)sorbitan trioleate, Tween 20, Tween 80, Vitamin E TPGS, and a mixture of any two or more thereof. 5. The formulation of claim 1, wherein the release agent has a molecular weight of at least about 1200 Daltons. 6. The formulation of claim 1, wherein the polyurethane based hydrophilic polymer has an exterior surface area of about 350 mm2 or greater. 7. The formulation of claim 6, wherein the polyurethane based hydrophilic polymer has an exterior surface area ranging from about 350 mm2 to about 1500 mm2. 8. The formulation of claim 1, wherein the formulation permits release of octreotide at an average rate ranging from about 75 μg per day to about 300 μg per day in vivo. 9. The formulation of claim 8, wherein the formulation provides an in vivo average Css of about 0.1 ng/mL to about 9 ng/mL of octreotide in the subject. 10. The formulation of claim 9, wherein the formulation provides an in vivo average Css of about 1 ng/mL to about 4 ng/mL of octreotide in the subject. 11. The formulation of claim 1, wherein the octreotide is octreotide acetate. 12. The formulation of claim 1, wherein the preparation comprises about 40 mg to about 120 mg of octreotide. 13. The formulation of claim 12, wherein preparation comprises about 50 mg of octreotide acetate. 14. The formulation of claim 12, wherein the preparation comprises about 85 mg of octreotide acetate. 15. The formulation of claim 1, wherein the preparation further comprises an excipient selected from the group consisting of: magnesium stearate, stearic acid, vegetable stearin, talc and silica. 16. The formulation of claim 1, wherein the preparation further comprises a compound selected from the group consisting of: hydroxypropylcellulose, hydroxyethyl cellulose, methyl cellulose, sodium carboxymethyl cellulose, modified starch and crosslinked polyvinyl pyrrolidone. 17. A method of decreasing GH levels or IGF-1 levels in a subject and/or treating an octreotide-sensitive disease, disorder or symptom, the method comprising subcutaneously implanting at least one dry implantable device comprising a preparation encased in a polyurethane based hydrophilic polymer, wherein the preparation comprises octreotide, wherein the formulation is effective to permit release of octreotide at a rate of about 30 μg to about 800 μg per day about six months in vivo, and wherein the polyurethane based hydrophilic polymer but not the preparation further comprises a release agent having a molecular weight of at least 1000 Daltons. 18. The method of claim 17, wherein the preparation comprises about 40 mg to about 120 mg of octreotide acetate. 19. The method of claim 17, wherein two implantable devices are implanted subcutaneously. 20. The method of claim 17, wherein the implantable device is sterilized by irradiation. 21. The method of claim 17, wherein the octreotide-sensitive disease, disorder or symptom is selected from the group consisting of: acromegaly or symptoms associated with acromegaly, a symptom associated with a carcinoid tumor, VIPoma or neuroendocrine tumor, carcinoid syndrome, proliferative diabetic retinopathy, rosacea, pancreatitis, gastrointestinal bleeding, pancreatic and intestinal fistulas, Graves-Basedow ophthalmopathy, glaucoma, and/or corneal disease associated with vasularization treating acromegaly or symptoms associated with acromegaly. 22. The method of claim 21, wherein a symptom associated with a carcinoid tumor, VIPoma or neuroendocrine tumor is selected from the group consisting of severe diarrhea, watery diarrhea or flushing episodes. 23. A kit comprising a formulation for the controlled release of octreotide after implantation into a subject comprising a preparation substantially encased in a polyurethane based hydrophilic polymer, wherein the preparation comprises octreotide, wherein the formulation is effective to permit release of octreotide at a rate of about 30 μg to about 800 μg per day over about six months in vivo, and wherein the polyurethane based hydrophilic polymer but not the preparation further comprises a release agent with a molecular weight of at least about 1000 Daltons.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (58)
Gaeta Laura S. L. (Foster City CA) Jones Howard (Poway CA) Albrecht Elisabeth (San Diego CA), Amylin agonist peptides and uses therefor.
Takizawa Atsushi,JPX ; Tomita Tadashi,JPX ; Nakayama Shigeo,JPX, Apparatus for supporting and connecting a magnetic field modulation head to be used for a photomagnetic recording includ.
Ayer Atul D. (Palo Alto CA) Burkoth Terry L. (Palo Alto CA) Kuczynski Anthony L. (Palo Alto CA) Deters Joseph C. (Napa CA), Controlled release dispenser comprising beneficial agent.
Szycher Michael (Lynnfield MA), Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-.
Moro Daniel G. (Randolph NJ) Ronel Samuel H. (Princeton NJ) Kuzma Petr (Monmouth Junction NJ), Hydrophilic composite polymer articles formed from a settable paste comprising a mixture of hydrophilic polymer and unsa.
Moro Daniel G. (Randolph NJ) Kuzma Petr (Monmouth Junction NJ) Quandt Harry (North Middletown NJ), Manufacture of water-swellable hydrophilic articles and drug delivery devices.
Eckenhoff ; deceased James B. ; Holladay Leslie A. ; Leonard ; Jr. John Joseph ; Leung Iris K. M. ; Tao Sally A. ; Magruder Judy A. ; Carr John P. ; Wright Jeremy C., Peptide/protein suspending formulations.
Ronel Samuel H. (Princeton NJ) D\Andrea Mark J. (Neshanic Station NJ) Dobelle William H. (New York NY) Klomp Gregory F. (New York NY) Hashiguchi Hiroshi (Riverdale NY), Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue an.
Williams Alan H. (Mount Duneed Via Belmont AUX) Staples Linton D. (East Kew AUX) Thiel William J. (Brighton AUX) Oppenheim Richard C. (Kew AUX) Clarke Iain J. (Malvern East AUX), Subdermal biocompatible implants.
Bodmer David,CHX ; Fong Jones W. ; Kissel Thomas,DEX ; Maulding Hawkins V. ; Nagele Oskar,CHX ; Pearson Jane E., Sustained release formulations of water soluble peptides.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.